A5092582775- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Protein Degradation and Inhibitors
- Angiogenesis and VEGF in Cancer
- Axon Guidance and Neuronal Signaling
Institut Gustave Roussy
2025
Université Claude Bernard Lyon 1
2023
Inserm
2023
Centre National de la Recherche Scientifique
2023
Centre de Recherche en Cancérologie de Lyon
2023
Centre Léon Bérard
2023
Abstract Netrin-1 is upregulated in cancers as a protumoural mechanism 1 . Here we describe netrin-1 upregulation majority of human endometrial carcinomas (ECs) and demonstrate that blockade, using an anti-netrin-1 antibody (NP137), effective reduction tumour progression EC mouse model. We next examined the efficacy NP137, first-in-class single agent, Phase I trial comprising 14 patients with advanced EC. As best response observed 8 stable disease (8 out 14, 57.1%) objective RECIST v.1.1...
PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis (CH), acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to expand under selective pressure DNA-damaging chemotherapy. However, whether promote development hematologic malignancies remains unclear. We characterized clinical genomic profiles 112 PPM1D-mutated patients across spectrum disorders using combination bulk single-cell...